The United Kingdom is set to roll out another trial to generate more data on the benefits and side effects of anti-Covid pill molnupiravir. The UK was the first country to licence the antiviral, developed by US drug maker Merck Sharp & Dohme, after which it was approved by other drug regulators including the United States Food and Drug Administration. The Drug Controller General of India cleared the oral drug for emergency use on December 28, though the Indian Council of Medical Research (ICMR) had expressed concerns over the safety profile of the drug.